Biotechnology

BRONCUS'S DISPOSABLE NEBULIZING MICRO-CATHETER FOR ENDOSCOPE WAS APPROVED FOR MARKETING IN CHINA AND ITS APPLICATIONS IN DRUG-DEVICE COMBINATION WILL BE BROADENED

HANGZHOU, China, Oct. 31, 2022 /PRNewswire/ -- Broncus is pleased to announce that onOctober 28, 2022, the Company's innovative product in the field of drug-device combination, "Mist FountainTM" (the "Product" or "Nebulizing Micro-Catheter"), a disposable nebulizing micro-catheter for endoscope, ...

2022-10-31 16:07 2112

Hinova Disclosed the Preclinical Results of HP518 (Oral AR PROTAC) at the 5th Annual TPD Summit

BOSTON, Oct. 29, 2022 /PRNewswire/ -- Hinova Pharmaceuticals Inc. (STAR: 688302), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers and metabolic diseases through targeted protein degradation technologies, today presented their preclinical results of ...

2022-10-29 05:30 8899

Pharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under Accelerated Assessment for leniolisib

Marketing authorisation in the European Economic Area anticipated in H1 2023 LEIDEN, Netherlands, Oct. 28, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM / Nasdaq: PHAR) announces today that its Marketing Authorisation Application (MAA) for leni...

2022-10-28 13:00 3731

Acceptance Of The Application For Clinical Trial Of Recbio Novel Adjuvanted Recombinant Quadrivalent HPV Vaccine

TAIZHOU, China, Oct. 28, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group")  is pleased to announce that, the Group has recently received a notice of acceptance from the National Medical Products Administration to accept the appli...

2022-10-28 11:10 2915

Sciwind Biosciences Announces Positive Interim Results from Ongoing Phase 2b Clinical Trial of XW003 (Ecnoglutide) in Patients with Obesity

-  Mean body weight loss of 11.1% in participants receiving once-weekly injections of 2.4 mg XW003 for 18 weeks -  88.5% and 57.7% of participants receiving 2.4 mg XW003 for 18 weeks achieved weight loss of≥5% and ≥10%, respectively  -  XW003 was safe and well tolerated, with an adverse event p...

2022-10-28 08:00 2154

Life sciences industry's highest achievers celebrated at prestigious Awards ceremony

AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards * Industry Leadership Award: Professors Steve Wilton AO and Sue Fletcher AO * Company of the Year: Telix Pharmaceuticals * Emerging Company of the Year: Fusetec AusBiotech Life Sciences Legacy Award: Dr Andrew Forrest AO a...

2022-10-27 22:39 2917

Cambrex to Invest $16.5 Million in New R&D Facility in Minneapolis, Minnesota and Expansion in Charles City, Iowa

EAST RUTHERFORD, N.J., Oct. 27, 2022 /PRNewswire/ -- Cambrex today announced it is investing in a new, 21,000-square-foot research and development facility in Minneapolis, Minnesota, expanding its capacity for small molecule development and manufacturing. Strategically located near the Minneapolis...

2022-10-27 18:00 1937

Telix Recognised as Company of the Year at AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards 2022

MELBOURNE, Australia, Oct. 27, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is today pleased to announce that it has been awarded Australian Company of the Year in the 2022 AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards, held today at t...

2022-10-27 10:23 2743

Forsea Attracts USD5.2M to Expand Cultivated Seafood, Without Harming Sea Life

Start-up pioneers organoid technology to make nature identical, cultured eel meat at cost parity REHOVOT, Israel, Oct. 27, 2022 /PRNewswire/ -- Forsea Foods, Ltd., a FoodTech start-up, is the first company to use organoid technology for culturing seafood products. With a goal of redressing the d...

2022-10-27 09:00 2078

SUCCESSFUL PASSING OF EU QP AUDIT ON TOT BIOPHARM'S COMMERCIAL PRODUCTION BASE FOR MONOCLONAL ANTIBODY DRUG SUBSTANCES AND ANTIBODY DRUG CONJUGATES

SUZHOU,China, Oct. 27, 2022 /PRNewswire/ -- TOT BIOPHARM International Company Limited (TOT BIOPHARM, Stock code: 1875.HK) has recently received a GMP compliance inspection report approved by aQualified Person ("QP") in the European Union ("EU") in respect of the manufacturing facilities and asso...

2022-10-27 08:00 2127

JW Therapeutics and 2seventy bio Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies

* Initial focus on accelerating development of 2seventy's MAGE-A4 program in solid tumors inChina SHANGHAI, China and CAMBRIDGE, Mass., Oct. 27, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and comme...

2022-10-27 07:53 3300

Telix and UniQuest to Collaborate on Radiolabelled Immune Targeting Peptide

MELBOURNE, Australia, Oct. 27, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a collaboration with UniQuest Pty Ltd (UniQuest), the commercialisation company of TheUniversity of Queensland (UQ), to develop a radiolabelled molecule targeting an im...

2022-10-27 06:44 2259

First satellite bioanalytical lab offers fastest option for PBMC processing in Australian clinical trials

THEBARTON, Australia, Oct. 26, 2022 /PRNewswire/ -- On 09 September 2022, Australia welcomed its first bioanalytical laboratory inside a Phase 1 clinical unit. Agilex Biolabs, Australia's largest bioanalytical laboratory, has established its first satellite processing unit on the fifth floor o...

2022-10-26 17:00 890

Metabolon Advances the Understanding of Inflammation and Inflammatory Response with New Oxysterols Targeted Panel

The new targeted metabolomics panel provides absolute quantitation for important bioactive intermediaries of inflammation and disease pathogenesis MORRISVILLE, N.C., Oct. 25, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of...

2022-10-25 20:03 2058

Clarivate Identifies Seven Innovators in New RNA Technology Companies to Watch Report

Report analyzes benefits, financing, R&D activity and more to reveal emerging standouts in medical science United States and Mainland China at the forefront of RNA technology advancement LONDON, Oct. 25, 2022 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted inform...

2022-10-25 15:19 1716

MiRXES collaborates with Plug and Play to launch Southeast Asia's first science-backed commercialization engine and validator program

MiRXES Translator Program will accelerate revenue growth of start-ups and importantly, adoption of preventive healthcare solutions globally SINGAPORE, Oct. 25, 2022 /PRNewswire/ -- MiRXES , a Singapore-headquartered biotechnology company focused on saving lives and improving...

2022-10-25 11:50 2465

T-cells treated by Turn Biotechnologies show increased cancer-killing effectiveness

* Preclinical data showing how ERA™, eTurna™ technologies turbocharge T-cell therapies presented at New Frontiers of RNA Nanotherapeutics meeting today * ERA™ boosts CAR T-cell efficacy by overcoming T-cell exhaustion that inhibits cancer cures * eTurna™ delivery platform delivers more healt...

2022-10-24 23:30 2638

deCODE genetics publishes multiomics study of nonalcoholic fatty liver disease

Scientists at deCODE genetics in Iceland have discovered rare, protective loss-of-function variants that point to potential drug targets for nonalcoholic fatty liver disease (NAFLD). REYKJAVIK, Iceland, Oct. 24, 2022 /PRNewswire/ -- Scientists at deCODE genetics, a subsidiary of Amgen, publish t...

2022-10-24 23:00 2680

Transcenta to Participate in Four Upcoming Conferences

SUZHOU, China, Oct. 24, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical-stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development, and manufacturing of antibody-based therapeutics, announces that the management ...

2022-10-24 21:00 3516

U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster for Adults

GAITHERSBURG, Md., Oct. 22, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received eme...

2022-10-22 03:25 7094
1 ... 54555657585960 ... 167